The Cleveland Clinic and Mount Sinai announced they will not administer Biogen’s controversial Aduhelm to patients. “Based on the current data regarding its safety and efficacy, we have decided not to carry aducanumab at this time,” the Cleveland Clinic said in a statement. (The New York Times)

A Centers for Disease Control and Prevention advisory panel will meet to consider giving an extra dose of vaccine to immunocompromised patients. Potential candidates for the shot include the 2 to 4% of the U.S. adult population with jeopardized immune systems, such as organ transplant recipients or cancer patients. (The Washington Post)

Shape Therapeutics has raised $112 million in a Series B to develop RNA editing, including for programs focused on Rett syndrome and Parkinson’s. Unlike CRISPR editing, Shape’s is focused on neurons. (Endpoints News)

Researchers have managed to achieve in vitro gametogenesis (IVG), or the ability to create gametes outside of the body, in a new study in mice. The research may pave a preliminary path forward for future fertility treatments. (STAT)

Researchers have created an experimental brain implant that translates brain signals into words on a computer. This could advance technology, broadly referred to as speech neuroprosthesis, that may eventually allow people to speak by thinking. (The Wall Street Journal)